01 10Vfend
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 346
2018 Revenue in Millions : 392
Growth (%) : -12
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 270
2019 Revenue in Millions : 346
Growth (%) : -22
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 267
2020 Revenue in Millions : 270
Growth (%) : -1
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 225
2021 Revenue in Millions : 267
Growth (%) : -16
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 187
2022 Revenue in Millions : 225
Growth (%) : -17
Main Therapeutic Indication : Anti-fungal
Currency : USD
2014 Revenue in Millions : -2.60%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anti-fungal
Currency : USD
2015 Revenue in Millions : 756
2014 Revenue in Millions : 682
Growth (%) : -10%
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2016 Revenue in Millions : 590
2015 Revenue in Millions : 682
Growth (%) : -13
Main Therapeutic Indication : Anti-fungal
Currency : USD
2017 Revenue in Millions : 421
2016 Revenue in Millions : 590
Growth (%) : -29
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2018 Revenue in Millions : 393
2017 Revenue in Millions : 421
Growth (%) : -7%
LOOKING FOR A SUPPLIER?